Recent development of methods for genome-wide identification of transcription factor binding sites by chromatin immunoprecipitation (ChIP) has led to novel insights into transcriptional regulation and greater understanding of the function of individual transcription factors. ChIP requires highly specific antibody against the transcriptional regulator of interest, and availability of suitable antibodies is a significant impediment to broader application of this approach. This limitation can be circumvented by tagging the transcriptional regulator of interest with a short bio epitope which is specifically biotinylated by the E. coli enzyme BirA. The biotinylated transcription factor can then be selectively pulled down on streptavidin beads under stringent conditions. This unit provides a detailed protocol for genome-wide location analysis of in vivo biotinylated transcription factors by streptavidin pull-down followed by high-throughput sequencing (bioChIP-seq). Curr. Protoc. Mol. Biol.
INTRODUCTION
Genome-wide identification of transcription factor binding sites provides insights into mechanisms of transcriptional regulation and an unbiased approach to identify genes and enhancers directly regulated by an individual transcription factor (Farnham, 2009 ). The standard approach involves immunoprecipitation of cross-linked chromatin (ChIP). The critical reagent for ChIP is the immunoprecipitating antibody. However, antibodies suitable for ChIP are not available for many transcription factors. In addition, an antibody may exhibit nonspecific binding that is idiosyncratic with respect to the particular antibody preparation, and the need for a different antibody for each factor complicates comparison between factors. An alternative approach is to express the transcription factor fused to a short bio peptide tag, which is specifically biotinylated by the E. coli enzyme BirA (Beckett et al., 1999; de Boer et al., 2003 ). The transcription factor can then be pulled down with high affinity under stringent conditions using the biotin-binding protein streptavidin. DNA bound to the tagged transcription factor can subsequently be identified by microarray hybridization (bioChIP-chip) or high-throughput sequencing (bioChIP-seq), thereby identifying the transcription factor binding locations genome-wide .
The Basic Protocol in this unit describes how to perform bioChIP-seq starting from cells expressing the biotinylated transcription factor. This protocol is similar in principle to the ChIP protocols presented in UNITS 21.3, 21.9, & 21.13 , but differs in the conditions used for pull-down on streptavidin beads versus immunoprecipitation. Additionally, the protocol is optimized for identification of pulled-down DNA by high-throughput sequencing rather
The authors used two constructs to permit titratable expression of biotinylated proteins of interest (Fig. 21.20 .1). The first, pCMV-rtTA-IRES-BirA, uses the CMV promoter to express the reverse tet activator protein (rtTA) and the E. coli protein BirA. The second construct expresses a tagged factor from a doxycycline (DOX)-regulated promoter (TRE).
The Gateway cloning system (Invitrogen) was used to facilitate placing the gene of interest into the TRE plasmid. Briefly, the flag-bio tag was cloned into a Gateway entry cassette in the plasmid pENTR-flbio. An ORF encoding the gene of interest (without the stop codon) is then PCR amplified and cloned between unique restriction sites in this plasmid, yielding a C-terminally tagged ORF. The Gateway LR Clonase is then used to transfer the tagged gene of interest into pTRE-gateway to yield the TRE-driven expression plasmid (generically called pTRE-GOI flbio ). pCMV-rtTA-IRES-BirA and pTRE-GOI flbio can be introduced into cells as dictated by the model system. For example, the constructs can be introduced by stable transfection, or by lentiviral or adenoviral expression. Pilot experiments are then performed to optimize the level of expression by adjusting the dosage of doxycycline.
The pCMV-rtTA-IRES-BirA, pENTR-flbio, and pTRE-gateway constructs are available through Addgene. 
GENOME-WIDE LOCATION ANALYSIS OF IN VIVO BIOTINYLATED TRANSCRIPTION FACTORS BY STREPTAVIDIN PULL-DOWN FOLLOWED BY HIGH-THROUGHPUT SEQUENCING (bioChIP-seq)
This protocol uses adherent cultured cells that express the transcription factor of interest. Protein-DNA complexes are stabilized by cross-linking with formaldehyde. Complexes containing the protein of interest are then isolated by pull down on streptavidin beads followed by extensive washing. Purified DNA is recovered after cross-link reversal. 3. Neutralize formaldehyde by adding 2.5 M glycine to a final concentration of 125 mM (1 ml of 2.5 M glycine per 20 ml medium). Incubate at room temperature for 5 min, shaking plates occasionally.
Materials
4. Decant medium completely and rinse cells with cold PBS three times. Do not allow the cells to become dry.
It is important to remove all fixative by thorough washing.
5. Add 5 ml cold PBS to each 15-cm dish. Use a cell lifter to scrape the cells off the dish. Transfer to a 50-ml centrifuge tube on ice. Add an additional 5 ml cold PBS to the dish, scrape one more time, and pool in the same 50-ml tube.
6. Centrifuge the cells 10 min at 3000 × g, 4 • C.
7. Aspirate as much of the cold PBS as possible. 11. After sonication, transfer cell lysates to microcentrifuge tubes and centrifuge 15 min at 20,000 × g, 4 • C, to pellet the cell debris.
12. Transfer the supernatant (containing the sheared chromatin) to two new microcentrifuge tubes.
The solution should be semi-transparent and slightly yellow.
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13. Estimate the sheared chromatin by pipetting 1 μl of supernatant into 99 μl TE buffer and measure the DNA concentration using a Nanodrop spectrophotometer. Use this value to equalize the amount of DNA used for streptavidin pull-down.
14. Save a 25-μl aliquot of supernatant as the input sample and store at −20 • C.
This sample will be reverse cross-linked at step 23.
Pull down biotinylated protein-DNA complexes on streptavidin 15. Prepare 50 μl protein A-magnetic beads and 50 μl streptavidin-magnetic beads for each ChIP reaction from ∼4 × 10 7 cells. Wash the beads three times with PBS/1% BSA, then block the streptavidin beads by incubating with 500 μl PBS/1% BSA for at least 1 hr in the 4 • C cold room.
This step can be performed while samples are being sonicated (in step 10).
16. Preclear the sheared chromatin: add the Protein A beads prepared in step 15 to each sample and incubate for 1 hr in the cold room.
This step removes proteins that bind nonspecifically to the bead matrix.
17. Briefly spin the sheared chromatin samples containing Protein A beads (allow the microcentrifuge to reach 6000 rpm, then stop), and place on magnetic stand for 30 sec.
Transfer the supernatant containing the sheared chromatin to a new siliconized, precooled microcentrifuge tube. Discard the Protein A beads.
18. Briefly spin the blocked streptavidin beads prepared in step 15. Place on magnetic stand for 30 sec. Decant the supernatant and resuspend the beads in 50 μl PBS/1% BSA. Add these beads to the sheared chromatin samples and incubate in the cold room for 1 hr to overnight.
19. Briefly centrifuge the samples and place on magnetic stand for 30 sec. Remove as much of the supernatant as possible using a pipettor with a 10-μl tip. 
This second TE wash in a new tube helps to reduce nonspecific background.
Elute and purify bioChIP DNA 22. Pellet beads and place on magnetic stand. Remove supernatant. To remove as much wash buffer as possible, briefly centrifuge again, and replace on magnetic stand. Remove as much residual supernatant as possible using a pipet. 23. To reverse cross-links, add 100 μl of SDS ChIP elution buffer to the pelleted beads and place in a 70 • C water bath overnight. At the same time, thaw the saved input chromatin aliquot from step 14, add 175 μl of SDS ChIP elution buffer, and reverse cross-link along with the pull-down samples.
24. Remove samples from the 70 • C water bath and cool to room temperature. Briefly spin, replace on magnetic stand, and decant the supernatant into a new siliconized microcentrifuge tube. Add 100 μl TE buffer to the beads, vortex vigorously for 10 sec, and combine the supernatant with the first eluate. Add 2 μl of 20 mg/ml proteinase K to each of the bioChIP and input chromatin samples, and incubate for 2 hr at 55 • C.
25. Add 2 μl of 10 mg/ml RNase A for 1 hr at 37 • C.
26. Purify the bioChIPed DNA using a QIAquick PCR purification kit following the manufacturer's protocol. Elute the bioChIPed DNA in 50 μl of the kit's EB buffer (10 mM Tris·Cl, pH 8.0) into a siliconized microcentrifuge tube. Validate bioChIP DNA by bioChIP-qPCR Quantitative PCR (qPCR) is an effective method to analyze DNA pulled down by bioChIP. bioChIP-qPCR can be used to validate a pulled-down sample or a bioChIP library prior to submission for high-throughput sequencing. bioChIP-qPCR can also be used to define the false-positive and false-negative rate for a set of peak calls obtained by bioChIP-seq.
The following steps do not provide detailed information about how to set up and run a qPCR experiment, but provide information about the application of qPCR to bioChIP. UNIT 15.8 provides more detailed information on performing qPCR.
27. For bioChIP-qPCR, use 1 μl of each bioChIPed DNA that results from the main bioChIP protocol as qPCR template. Prepare negative control samples from (1) the input chromatin after cross-link reversal, and (2) bioChIP of the sample expressing BirA but not a bio epitope-tagged protein.
Design primers for the genomic region of interest.
A pair of primers to a region of the genome not anticipated to be pulled down in the bioChIP reaction should be used as an internal control to monitor the extent of nonspecific pull-down. As an example, the authors used a region in the first intron of the murine Actb gene:
Forward: 5 -CGTATTAGGTCCATCTTGAGAGTACACAGTATT-3
Reverse: 5 -GCCATTGAGGCGTGATCGTAGC-3 . 
OPTIMIZATION OF SONICATION CONDITIONS FOR bioChIP-seq
Proper fragmentation of chromatin is essential to achieving good results (see Critical Parameters). On most sonicators, the variables that can be adjusted are amplitude, pulse-on time, rest time, and cycle number. Specific values are provided here for the Misonix 4000 with microtip, but individual settings will need to be determined empirically depending on the sonicator setup. Input cell number, sample volume, and sonication buffer components all affect sonicator settings, and therefore pilot experiments should use conditions that reflect those that will be used in actual experiments.
Amplitude is the percent of maximal power. Insufficient power will lead to long sonication times and incomplete fragmentation. Excessive power leads to foaming. The authors use 70% amplitude. Pulse-on time is the time per cycle during which sonication occurs. Excessive pulse-on time causes local heating, which damages chromatin. The authors use a pulse-on time of 15 sec. Rest time is the time per cycle during which no sonication occurs. This is required for dispersal of heat. We use a rest time of 1 min. Cycle number is the number of sonication cycles. After establishing the other settings, cycle number is the main variable that requires adjustment depending on different cell types, but is typically between 20 and 32 cycles.
All sonication is performed in the cold room in an ice/water bath. The sonicator tip needs to be positioned carefully as the sonication conditions depend on the volume being sonicated and the position of the tip within the sample. Also, the tip can be damaged if it touches the sample tube.
To optimize sonication conditions, pilot experiments should be performed on the cell type of interest.
For materials, see Basic Protocol.
1. Proceed through steps 1 to 11 of the Basic Protocol, preparing three chromatin samples.
2. Sonicate the chromatin samples, keeping the amplitude, pulse-on, and pulse-off times constant while varying the number of cycles. 4. Repeat steps 2 and 3, adjusting the amplitude and cycle number to achieve an average fragment size of ∼100 to 300 bp. Figure 21 .20.2.
An example of two different sonication conditions is shown in
SUPPORT PROTOCOL 2
CONVERSION OF bioChIP-seq DNA TO A LIBRARY FOR SEQUENCING ON THE ILLUMINA GENOME ANALYZER 2
ChIP-seq library preparation is performed according to the Illumina ChIP-seq preparation kit manual, but with a few modifications as described below. Use siliconized microcentrifuge tubes throughout this procedure. 4. Prepare the following mix and incubate for 30 min at 37 • C:
Materials
34 μl DNA sample (from step 3) 5 μl Klenow buffer 10 μl 1 mM dATP 1 μl Klenow exo -(3 to 5 exo minus).
5. Purify DNA on one QIAquick PCR Purification Kit column, following the manufacturer's instructions. Elute in 34 μl of the kit's EB buffer.
6. Dilute the Adapter oligo mix 1:20 with water to adjust for the smaller quantity of DNA. Prepare the following reaction mix and incubate for 15 min at room temperature.
10 μl DNA sample from step 5 15 μl T4 DNA ligase buffer 1 μl diluted adapter oligo mix (see above) 4 μl T4 DNA ligase.
7. Purify DNA on one MinElute PCR Purification Kit column, following the manufacturer's instructions. Elute in 10 μl of the kit's EB buffer. Then add another 10 μl EB buffer and elute a second time. Combine the two eluates.
8. Prepare a 100-ml, 2% agarose gel with 1× TAE buffer (UNIT 2.5A). Just before pouring the gel, add ethidium bromide (EtBr) to 400 ng/ml.
9. Add 2 μl of 10× DNA loading buffer and an additional 2 μl of 80% glycerol to the DNA from the purified ligation reaction (step 7). 13. Using a clean razor blade, excise a gel slice from the sample lane between ∼200 and 400 bp (corresponding to the peak chromatin size plus 92 bp of ligated adapters). Photograph the gel before and after cutting out the gel slice.
No band will be evident due to low sample concentration (see Fig. 21.20.3 ).
14. Cut a slice of the same size from an empty well on the same gel and process this sample through gel purification and PCR.
No visible PCR product should be present.
15. Recover DNA from the gel slices using the QIAquick Gel Extraction Kit. Elute DNA in 36 μl EB buffer.
Prepare the following PCR reaction mix:
36 μl DNA (from step 15) 10 μl 5× Phusion buffer 1.5 μl 10 mM dNTP mix 1.5 μl PCR primer 1.1 1 μl Illumina PCR primers 1.1 1 μl Illumina PCR primers 2.1 0.5 μl Phusion polymerase. 17. Amplify using the following PCR protocol: 18. Purify PCR products on one MinElute PCR Purification Kit column, following the manufacturer's instructions. Elute in 15 μl of the kit's EB buffer.
19. Purify again on a 2% agarose gel, following steps 8 to 14 of this protocol; this time a band should be present that corresponds to the ChIP-seq library (Fig. 21.20.3) . Purify DNA from the gel slice using the MinElute Gel Extraction Kit. Elute in 10 μl of the kit's EB buffer. Add another 10 μl and repeat. Pool the two eluates.
This second gel-purification step is essential to remove primer dimers and excess oligonucleotides. Running the gel at low voltage for several hours will enhance separation of the desired product from contaminants.
20. Perform quantitation, quality control, and sequencing with the Illumina GA2. 
REAGENTS AND SOLUTIONS
Concentrated protease inhibitor cocktail
Dissolve one Roche Protease Inhibitor Cocktail tablet (cat. no. 11697498001) in 1 ml distilled water. Store up to 1 month at −20 • C.
High-salt buffer
50 mM HEPES, pH 7.5 500 mM NaCl 1 mM disodium EDTA 0.1% (w/v) sodium deoxycholate 1% (v/v) Triton X-100 Store at room temperature for up to several months bioChIP-seq
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Hypotonic buffer 20 mM HEPES pH 7.5 10 mM KCl 1 mM EDTA 0.1 mM activated Na 3 VO 4 (to activate the sodium orthovanadate, boil a 200 mM stock solution for 10 min, then cool to room temperature and add the appropriate amount to the buffer mixture) 0.2% (v/v) Nonidet P-40 (NP-40) 10% (v/v) glycerol Store at 4
• C with the above components up to several months At time of use, add: Fresh DTT to 1 mM PMSF to 1 mM 1 part concentrated protease inhibitor cocktail per 1000 parts buffer LiCl buffer 10 mM Tris·Cl, pH 8.1 (APPENDIX 2) 250 mM LiCl 1 mM disodium EDTA 0.5% (v/v) Nonidet P-40 (NP-40) 0.5% (w/v) sodium deoxycholate Store at room temperature for up to several months SDS ChIP elution buffer 50 mM Tris·Cl, pH 8.1 (APPENDIX 2) 10 mM disodium EDTA 1% (w/v) SDS Store at room temperature for up to several months
SDS wash buffer
Prepared from 20% SDS stock solution (APPENDIX 2) by dilution in nuclease-free water. Store at room temperature for up to several months
TE buffer
10 mM Tris·Cl, pH 7.5 (APPENDIX 2) 1 mM disodium EDTA Store at room temperature for up to several months
COMMENTARY Background Information
Chromatin immunoprecipitation (ChIP) has become the method of choice to identify transcription factor chromatin occupancy in vivo. Genome-wide application of this approach by hybridization-based (ChIP-chip; UNIT 21.13) and high-throughput sequencingbased UNIT 21.19) technologies has fueled rapid advances in the understanding of transcriptional regulation. While hybridization-based approaches continue to be useful for targeted analyses, sequencing-based approaches are both less expensive and have greater dynamic range. Therefore, ChIP-seq (UNIT 21.19) has become the method of choice for unbiased genome-wide studies.
One barrier to application of ChIP approaches is availability of "ChIP-grade" antibodies that efficiently and specifically pull down the protein of interest even after treatment with formaldehyde. This limitation can be circumvented by placing an epitope tag on the protein of interest, which allows different factors to be pulled down by a uniform method, facilitating comparisons between factors. The bio tag is a 22-amino acid sequence that is specifically biotinylated by the E. coli enzyme BirA. In BirA-expressing cells,
21.20.13
Current Protocols in Molecular Biology
Supplement 92 bio-tagged proteins become biotinylated, allowing them to be pulled down with extraordinary affinity onto immobilized streptavidin. de Boer, Strouboulis, and colleagues used the bio tag for single-step affinity purification of transcription factors from mammalian cells (de Boer et al., 2003) , and Orkin and colleagues applied the technique to genome-wide location analysis .
Critical Parameters
Expression of tagged protein
The strategy for expressing the biotinylated protein of interest depends on the gene-transfer technology that is optimal for the model system under study. Important factors to consider are expression of the correct protein isoform, the fraction of cells that express the biotinylated protein (i.e., gene transfer efficiency), and the level of expression in expressing cells. Obviously, when a gene can be expressed as multiple different isoforms as a result of alternative promoter usage or alternative splicing, it is desirable to select the isoform relevant to the system under study. Obtaining high gene-transfer efficiency improves the signalto-noise ratio and decreases the number of input cells required, since only expressing cells contribute to the ChIP signal but all cells contribute to noise. Within expressing cells, it is desirable to achieve expression at nearendogenous levels, as marked overexpression may lead to occupancy of nonphysiological binding sites. Using a titratable expression system, such as that based on the reverse tetactivator, facilitates optimization of expression level.
Chromatin preparation
To fix dynamic protein-DNA complexes under the conditions being studied, it is desirable to cross-link proteins to DNA with a minimum of intervening manipulations. While in some cases fluorescence-activated cell sorting (FACS) may be required to isolate the population of interest, it is possible that chromatin occupancy measured after long FACS procedures may not be representative of the condition of interest. If cells need to be frozen prior to proceeding with bioChIP, certainly it is desirable to fix the cells prior to freezing. The extent of cross-linking is also an important parameter. Under-cross-linking reduces signal, while over-cross-linking can impair chromatin fragmentation and increase nonspecific background.
Adequate fragmentation of chromatin to a mean fragment size of 150 to 300 bp is crucial for success of bioChIP-seq. Insufficient fragmentation leads to inefficient use of input material. More importantly, it reduces resolution of bioChIP-seq peaks and increases background. Sonication conditions vary by target cells and growth conditions, so pilot experiments should be performed to empirically optimize sonication conditions prior to proceeding with preparation of bioChIP-seq samples.
Controls
Two essential controls for bioChIP-seq experiments are input chromatin and chromatin pull-down in the presence of BirA but the absence of bio-tagged protein. Input chromatin consists of sonicated chromatin prior to pulldown. This sample establishes the background distribution of chromatin fragments, which is not uniform because of nonrandom chromatin fragmentation by sonication. The BirA sample controls for background caused by endogenously biotinylated proteins and nonspecific protein binding to streptavidin beads.
High-throughput sequencing
36-bp single-end or paired-end sequencing can be used for bioChIP-seq. Paired-end sequencing (UNIT 21.15) improves mappability of reads and directly yields the pulled-down genomic fragment. With single-end sequencing, a greater fraction of reads cannot be uniquely mapped. In addition, the other end of the genomic fragment must be inferred from the average length of the material incorporated into the sequencing library. This potentially reduces the precision with which bound DNA peaks can be identified. On the other hand, paired-end sequencing is more expensive, and many "peak caller" software packages do not make use of the paired-end sequencing data.
The depth of sequencing required for adequate detection of transcription factor binding sites depends to some extent on the number of expected binding sites and how "adequate detection" is defined. Initially, it was expected that a saturation point would be reached, beyond which additional sequencing would not yield substantially more binding sites. However, simulations have demonstrated that this is not the case when statistical thresholds are used (Park, 2009) , perhaps because increased sequencing depth permits more sensitive detection of low-affinity binding sites. However, bioChIP-seq 21.20.14 Supplement 92
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Analysis
The millions of sequence reads generated by a bioChIP-seq experiment require computational analysis to identify enriched regions. In brief, sequence reads are aligned to the genome, using short read aligners such as Bowtie, Eland, Maq, and Novoalign. Then a "peak caller" scans the genome to identify areas enriched for aligned reads (Park, 2009) . Different peak caller implementations are available, each with different strengths and weaknesses. A number of these were recently reviewed (Pepke et al., 2009) .
For bioChIP-seq data, we have used CisGenome (Ji et al., 2008) and Sole-Search (Blahnik et al., 2010) . We compared the experimental bioChIP sample to Input. To control for background binding or endogenously biotinylated proteins, we compared the BirA sample to Input. Peaks from the BirA versus Input comparison are then subtracted from the bioChIP versus Input comparison. In our experience, there has been little overlap between peaks called in the experimental and negative control comparisons.
Anticipated Results
Depending on the tagged transcription factor and the peak calling parameters, bioChIPseq generally yields between 1,000 and 50,000 transcription factor binding sites. Important properties to experimentally define for this transcription-factor binding-site list are the false-positive and false-negative rates. The false-negative rate is the frequency at which "gold standard" transcription factor binding sites established by prior experimentation fail to be identified in the observed list of transcription factor binding sites. The "gold standard" list should be validated in the specific experimental system used for bioChIP-seq through bioChIP-qPCR. Conversely, the false-positive rate is the frequency that transcription factor binding sites identified by bioChIP-seq fail to be validated by bioChIP-qPCR. We typically observed false positive rates of 0% to 25%; if the false-positive rate is unacceptably high, then more stringent peak-calling parameters may be necessary. On the other hand, unacceptably high false-negative rates may be due to many factors, such as excessively stringent peak-calling parameters, inadequate sequencing depth, or low signal or high background in the chromatin pull-down. Other properties of bioChIP-seq peaks that might validate the data are identification of the expected transcription factor binding motif among the bioChIP-seq peaks, and evolutionary conservation of the bioChIP-seq peaks.
Time Considerations
